[{"data":1,"prerenderedAt":4},["ShallowReactive",2],{"raw-en-articles\u002Fpharmaceutical-ai-governance-from-discovery-to-regulated-submission":3},"---\ntitle: Pharmaceutical AI governance from discovery to regulated submission\ndescription: Governance semantics for Pharmaceutical AI governance from discovery to regulated submission\nlang: en\nnavigation:\n  enabled: false\n  section: articles\n  order: 30\ntags:\n  - ai\n  - governance\n  - pharma\n---\nThe difficulty with AI controls is not intent—it is consistency across tools, teams, and decisions.\n\n## Why this matters\n\nWithout shared meaning, each team rebuilds governance controls separately—multiplying risk.\n\n## What this looks like in practice\n\n- An auditor traces AI governance decisions from policy to code to test results without guessing.\n- Different teams use the same terms to mean the same thing, even when implementing differently.\n- Risk classifications are consistent whether assessed by humans, tools, or external regulators.\n\n## How teams use it\n\n- defining bias and fairness in ways that survive across ML frameworks and deployment contexts\n- aligning audit trails so compliance evidence is usable by multiple teams without rewriting\n- connecting model governance to software supply chain controls\n\nShared AI semantics turn governance from a bottleneck into a capability.\n",1776235588261]